These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26451316)

  • 1. An optimized peptide vaccine strategy capable of inducing multivalent CD8
    Cho HI; Jung SH; Sohn HJ; Celis E; Kim TG
    Oncoimmunology; 2015 Nov; 4(11):e1043504. PubMed ID: 26451316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
    Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
    Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.
    Cho HI; Celis E
    Cancer Res; 2009 Dec; 69(23):9012-9. PubMed ID: 19903852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.
    Shin AR; Lee SE; Choi H; Sohn HJ; Cho HI; Kim TG
    Br J Cancer; 2020 Sep; 123(6):919-931. PubMed ID: 32595211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
    Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
    Cell Biosci; 2016; 6():16. PubMed ID: 26918115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
    Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
    Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
    Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
    Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA is an efficient booster of dendritic cell-based vaccine.
    Li J; Valentin A; Beach RK; Alicea C; Felber BK; Pavlakis GN
    Hum Vaccin Immunother; 2015; 11(8):1927-35. PubMed ID: 26125100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
    Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.
    Schuurhuis DH; van Montfoort N; Ioan-Facsinay A; Jiawan R; Camps M; Nouta J; Melief CJ; Verbeek JS; Ossendorp F
    J Immunol; 2006 Apr; 176(8):4573-80. PubMed ID: 16585547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect.
    Hofer T; Rossi M; Carboni S; Di Berardino Besson W; von Laer D; Wollmann G; Derouazi M; Santiago-Raber ML
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.